AACR 2023 | TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients

Khandan Keyomarsi, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on Trefoil Factor 1 and 3 (TFF1 and TFF3) as potential biomarkers of response to CDK4/6 inhibitors in patients with ER-positive, HER2-negative breast cancer. An analysis of breast cancer cell lines revealed the two secretory proteins to be promising biomarkers, enabling enhanced selection of patients who will benefit from CDK4/6 inhibitors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.